Peptides · Peptide comparison
Gonadorelin (GnRH) vs Triptorelin
The master hormone that controls your reproductive system and fertility
GnRH agonist that helps manage prostate cancer, endometriosis, and early puberty by controlling sex hormones
- Hormone Support
- Hormone Support
At a glance
Quick comparison
Efficacy
Benefit ratings
Reproductive Health
Hormone Balance
Ovulation Support
Hormone Regulation
Cancer Management
Endometriosis Relief
Technical data
Compound specifications
Gonadorelin (GnRH)
- Molecular formula
- C55H75N17O13
- Molecular weight
- 1182.3
- Half-life
- 2-4 minutes
- Bioavailability
- Varies by route: ~5-20% (intranasal), 100% (IV/IM injections)
- CAS number
- 34973-08-5
Triptorelin
- Molecular formula
- C64H82N18O13
- Molecular weight
- 1311.4 g/mol
- Half-life
- 2-3 hours (free peptide); 2-4 weeks (depot pamoate formulations)
- Bioavailability
- ~100% (intramuscular/subcutaneous injection)
- CAS number
- 57773-63-4
Protocols
Dosing compared
Gonadorelin (GnRH)
Subcutaneous
- 100 mcgSingle dose · One-time diagnostic testFDA-labeled gonadotropin (LH/FSH) stimulation test for pituitary reserve; 100 mcg given once subcutaneously (or IV), with LH measured at 0, 15, 30, 45, 60 and 120 minutes (Factrel) [4].
Intravenous
- 5 mcg per pulse (range 1-20 mcg)Every 90 minutes via pulsatile pump · One or more ovulatory cycles; reassessed at 21-day intervalsFDA-labeled pulsatile regimen for ovulation induction in hypothalamic amenorrhea (Lutrepulse); intravenous pulsatile delivery gave better results than subcutaneous [5]. The 2-4 minute half-life makes pulsatile delivery essential.
Triptorelin
Intramuscular injection
- 3.75 mgOnce every 4 weeks · Ongoing while indicatedFDA-labeled 1-month depot (Trelstar) for advanced prostate cancer; single IM injection into either buttock [5].
- 11.25 mgOnce every 12 weeks · Ongoing while indicatedFDA-labeled 3-month depot (Trelstar). Strengths are not additive; chosen by desired interval [5].
- 22.5 mgOnce every 24 weeks · Ongoing while indicatedFDA-labeled 6-month depot (Trelstar for prostate cancer; Triptodur 22.5 mg for central precocious puberty, ages 2+) [5][6].
Applications
Best suited for
Gonadorelin (GnRH)
- Improving fertility and conception chances
- Gonadorelin (GnRH) is particularly well-suited for individuals focused on improving fertility and conception chances. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Regulating irregular menstrual cycles
- Gonadorelin (GnRH) is particularly well-suited for individuals focused on regulating irregular menstrual cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Enhancing reproductive hormone levels
- Gonadorelin (GnRH) is particularly well-suited for individuals focused on enhancing reproductive hormone levels. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Supporting natural pregnancy attempts
- Gonadorelin (GnRH) is particularly well-suited for individuals focused on supporting natural pregnancy attempts. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Triptorelin
- Managing advanced prostate cancer when combined with other treatments
- Triptorelin is particularly well-suited for individuals focused on managing advanced prostate cancer when combined with other treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Relieving severe endometriosis pain and symptoms
- Triptorelin is particularly well-suited for individuals focused on relieving severe endometriosis pain and symptoms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Delaying puberty development in children with early sexual maturation
- Triptorelin is particularly well-suited for individuals focused on delaying puberty development in children with early sexual maturation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety profile
Side effects
Gonadorelin (GnRH)
Common
- Mild headache
- Local injection site reactions (redness, swelling)
- Temporary hot flashes
- Mood changes or emotional sensitivity
- Nausea or mild stomach upset
- Allergic skin reactions
- Dizziness or lightheadedness
- Temporary changes in vision
- Joint or muscle aches
- Insomnia or sleep disturbances
- Severe allergic reactions (difficulty breathing, swelling)
- Severe hormonal imbalance symptoms
- Ovarian hyperstimulation syndrome (OHSS)
- Signs of blood clots (chest pain, leg swelling)
- Severe mood changes or depression
Serious
- Severe allergic reaction
Triptorelin
No side effects recorded.
Research status
Safety & evidence
Gonadorelin (GnRH)
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Previously FDA approved: FACTREL (1982) as a diagnostic test of pituitary gonadotropin reserve and LUTREPULSE (1989) for ovulation induction. Both human products are discontinued in the US.
- Safety overview
- Gonadorelin is native GnRH and carries the safety profile established over 40+ years of clinical use in reproductive endocrinology. As the body's natural hormone, it produces minimal local side effects when dosed appropriately. The critical safety concern with gonadorelin is the initial flare effect within 24-48 hours of first dose—temporary elevation in FSH and LH—which can paradoxically suppress sex hormones before the desired stimulation occurs. This flare makes gonadorelin unsuitable for some conditions and explains why synthetic analogs (agonists, antagonists) are preferred in many modern fertility protocols.
Contraindications
- Pregnancy or breastfeeding
- Hormone-sensitive cancers (breast, prostate, ovarian)
- Severe pituitary or hypothalamic disease
- Undiagnosed abnormal vaginal bleeding
- Known hypersensitivity to GnRH
Triptorelin
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- FDA approved for this use
- Safety overview
- Triptorelin (GnRH agonist) has extensive FDA-approved safety data spanning decades for prostate cancer, endometriosis, and precocious puberty indications. Initial testosterone surge upon initiation ("flare reaction") can worsen prostate cancer or spinal cord compression symptoms, requiring careful patient monitoring in first 1-2 weeks and use of androgen antagonists in high-risk patients. Hypogonadal effects including hot flashes, sexual dysfunction, and bone loss develop predictably with chronic GnRH suppression; bone density monitoring is recommended in patients on therapy >6 months.
Contraindications
- Pregnancy (can affect fetal development)
- Undiagnosed vaginal bleeding
- Known hypersensitivity to GnRH agonists
- Severe untreated depression
- Active spinal cord compression in prostate cancer (requires urgent decompression)
Decision guide
Which is right for you?
Gonadorelin (GnRH)
Choose Gonadorelin (GnRH) if…
- Improving fertility and conception chances
- Regulating irregular menstrual cycles
- Enhancing reproductive hormone levels
- Supporting natural pregnancy attempts
Triptorelin
Choose Triptorelin if…
- Managing advanced prostate cancer when combined with other treatments
- Relieving severe endometriosis pain and symptoms
- Delaying puberty development in children with early sexual maturation